Name: Cancer-Causing Viruses and Their Inhibitors (en Inglés)
Price: 197.27 USD
Availability: InStock
Author: Gupta, Satya Prakash
ISBN: 9781466589773

portada Cancer-Causing Viruses and Their Inhibitors (en Inglés)

Formato

Libro Físico

Editorial

CRC Press

Autor

Gupta, Satya Prakash

Idioma

Inglés

N° páginas

511

Encuadernación

Tapa Dura

Dimensiones

22.9 x 15.5 x 3.3 cm

Peso

0.84 kg.

ISBN13

9781466589773

N° edición

Categorías

Ciencias básicas de la medicina preclínica
Oncología
Microbiología (no médica)

Cancer-Causing Viruses and Their Inhibitors (en Inglés)

Gupta, Satya Prakash (Autor) · CRC Press · Tapa Dura

Libro Nuevo

$ 197.27

$ 389.65

Ahorras: $ 192.38

49% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 24 de Julio y el Lunes 05 de Agosto.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Cancer-Causing Viruses and Their Inhibitors (en Inglés)"

Cancer-causing viruses, also called oncoviruses, play a key role in the development of certain cancers. They contribute to genetic changes that disrupt the cell cycle machinery, interfering with functions such as cell growth. Cancer-Causing Viruses and Their Inhibitors presents a plethora of research from internationally reputed contributors who discuss different types of oncoviruses, their mechanisms of invasion and growth, and their life cycles. The book begins with an overview of the oncoviruses discovered to date and includes a brief description of their structures, genotypes, replication, and mechanisms of infection leading to cancers. It then explores several of these viruses in detail, including: Human T-cell leukemia virus type 1 (HTLV-1) Hepatitis C virus (HCV) Epstein-Barr virus (EBV) Human papilloma virus (HPV) Human herpes virus 8 (HHV-8)/Kaposi's sarcoma-associated herpes virus (KSHV) Human immunodeficiency virus (HIV/AIDS) Oncolytic viruses This book is an essential reference for those working in virology, oncology, and biotechnology. The discoveries presented will enable researchers and clinicians to optimize both historical and current approaches to anti-viral therapies.